DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Bi-terminal pegylated integrin-binding peptides and methods of use thereof

Abstract

The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.

Inventors:
;
Issue Date:
Research Org.:
Univ. of California, Davis, CA (United States)
Sponsoring Org.:
USDOE; National Institutes of Health (NIH)
OSTI Identifier:
1986773
Patent Number(s):
11485758
Application Number:
17/131,324
Assignee:
The Regents of the University of California (Oakland, CA)
DOE Contract Number:  
SC0002061; 1RC4EB012836-01
Resource Type:
Patent
Resource Relation:
Patent File Date: 12/22/2020
Country of Publication:
United States
Language:
English

Citation Formats

Hausner, Sven H., and Sutcliffe, Julie L. Bi-terminal pegylated integrin-binding peptides and methods of use thereof. United States: N. p., 2022. Web.
Hausner, Sven H., & Sutcliffe, Julie L. Bi-terminal pegylated integrin-binding peptides and methods of use thereof. United States.
Hausner, Sven H., and Sutcliffe, Julie L. Tue . "Bi-terminal pegylated integrin-binding peptides and methods of use thereof". United States. https://www.osti.gov/servlets/purl/1986773.
@article{osti_1986773,
title = {Bi-terminal pegylated integrin-binding peptides and methods of use thereof},
author = {Hausner, Sven H. and Sutcliffe, Julie L.},
abstractNote = {The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Nov 01 00:00:00 EDT 2022},
month = {Tue Nov 01 00:00:00 EDT 2022}
}

Works referenced in this record:

The Epithelial Integrin αvβ6 Is a Receptor for Foot-and-Mouth Disease Virus
journal, January 2000


Targeted Drug Delivery with an Integrin-Binding Knottin–Fc–MMAF Conjugate Produced by Cell-Free Protein Synthesis
journal, June 2016


Modified plant viruses as vectors
patent, August 2000


Fluorescent Amphiphilic PEG‐Peptide‐PEG Triblock Conjugate Micelles for Cell Imaging
journal, March 2014


Rgd and Other Recognition Sequences for Integrins
journal, November 1996


Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide
journal, January 2007


Structure and receptor binding
journal, January 2003


Effect of pegylation on pharmaceuticals
journal, March 2003


The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution
journal, February 1989


Effective drug delivery by PEGylated drug conjugates
journal, February 2003


MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide
journal, April 2004


Exact and approximate rebinning algorithms for 3-D PET data
journal, April 1997


Bio-Functionalized Stimulus-Responsive Dissolvable Peg-Hydrogels
patent-application, November 2013


Identification of Pancreatic Cancer Stem Cells
journal, February 2007


Absence of αvβ6 Integrin Is Linked to Initiation and Progression of Periodontal Disease
journal, May 2008


PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
journal, October 2006


Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival
journal, January 2007


Immunomodulatory peptides
patent, December 2014


Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides
journal, March 2002


Bioactive hydrogels made from step-growth derived PEG–peptide macromers
journal, May 2010


Facile formation of dynamic hydrogel microspheres for triggered growth factor delivery
journal, March 2011


Definition of an Unexpected Ligand Recognition Motif for αvβ6 Integrin
journal, January 1999


PEGylation, successful approach to drug delivery
journal, November 2005


PET/CT: Form and Function
journal, February 2007


Chemistry for peptide and protein PEGylation
journal, June 2002


18Fluorodeoxyglucose-Positron Emission Tomography in the Management of Patients With Suspected Pancreatic Cancer
journal, May 1999


Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma
journal, January 2005


αvβ6-Fyn Signaling Promotes Oral Cancer Progression
journal, October 2003


Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein.
journal, March 1992


Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
journal, January 2004


Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment
journal, February 2004


Specificity of the VP1 GH Loop of Foot-and-Mouth Disease Virus for αv Integrins
journal, October 2006


Bi-terminal pegylated integrin-binding peptides and methods of use thereof
patent, February 2021


PEG–Peptide Conjugates
journal, April 2014


Long-term survival after pancreatic cancer treatment
journal, October 2007


Diagnosis of pancreatic carcinoma: role of FDG PET.
journal, December 1998


Structure of a major immunogenic site on foot-and-mouth disease virus
journal, April 1993


Integrin Structure, Activation, and Interactions
journal, January 2011


Implications of PET based molecular imaging on the current and future practice of medicine
journal, January 2004


High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner
journal, April 1998


The dawning era of polymer therapeutics
journal, May 2003


Solid-Phase Synthesis of 2-[ 18 F]Fluoropropionyl Peptides
journal, July 2006


Effects of PEG conjugation on insulin properties
journal, June 2002


The Effect of Bi-Terminal PEGylation of an Integrin  v 6-Targeted 18F Peptide on Pharmacokinetics and Tumor Uptake
journal, March 2015


Preoperative evaluation of pancreatic adenocarcinoma
journal, July 2008